AUROPHARMA
Aurobindo Pharma Limited (auropharma) Reports Q4 FY26 Results: Revenue Up 5.6% Yoy
Aurobindo Pharma Limited (AUROPHARMA) announced consolidated financial results for Q4 and FY 2026, showing a 5.6% YoY revenue increase to INR 8,853 Cr.
Aurobindo Pharma Limited (AUROPHARMA) announced its consolidated financial results for the quarter and year ended March 31, 2026. The company reported a revenue increase of 5.6% year-on-year to INR 8,853 Cr, driven by growth across all its business segments. Notably, the European business achieved a significant milestone by crossing €1bn in revenues for FY26, with a quarterly revenue jump of 30.2% to INR 2,795 Cr (EUR 261 million).
Key Financial Highlights
The company’s net profit for the quarter stood at INR 921 Cr, and the EBITDA margin before R&D was 20.3%. Aurobindo Pharma also received final approval for 9 ANDAs from the USFDA, further strengthening its regulatory portfolio. The company’s net cash position remained strong after the acquisition of Khandelwal laboratories’ non-oncology business for USD 317mn.
Forward-Looking Statement
Commenting on the performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director, said, ‘We are encouraged by our performance for the quarter and the year, reflecting the resilience of our business model and the strength of our extensive product portfolio. With ongoing investments in capacity expansion and the stabilization of recently commercialized facilities, we remain confident in our ability to support sustainable growth and create long-term value for our stakeholders.’
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Aurobindo Pharma Limited
Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Aurobindo gains 33.5% over three months and trades near its 52-week highs. The PEG of 2.68 is on the high side. However, it is acceptable for a quality compounder with a strong moat. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. RSI hits 76, a level that signals the stock runs hot. Notably, buyers drove volume on 20 recent sessions — though at these levels, some profit-taking is normal. The business grows revenue at 10.3% and profits at 9.6%, with D/E of 0.27. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.68 premium is usually justified. Check Fundamentals of Aurobindo Pharma Limited.
AUROPHARMA
Aurobindo Pharma Limited Receives Final Approval for Perampanel Tablets from USFDA
Aurobindo Pharma Limited (NSE: AUROPHARMA) receives final approval from USFDA for Perampanel Tablets, set to launch in Q3FY27.
Aurobindo Pharma Limited (NSE: AUROPHARMA) is pleased to announce the receipt of final approval from the US Food & Drug Administration (USFDA) to manufacture and market Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. These tablets are bioequivalent and therapeutically equivalent to the reference listed drug, Fycompa® Tablets, of Catalyst Pharmaceuticals, Inc. The product will be manufactured at Unit -IV of APL Healthcare, a wholly-owned subsidiary of the Company, and is set to launch in Q3FY27. The approved product has an estimated market size of US$ 67 million for the twelve months ending August 2026, according to IQVIA MAT.
Significance of Approval
This approval marks a significant milestone for Aurobindo Pharma as it expands its portfolio of CNS products. Perampanel Tablets are indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 4 years and older and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older.
Company’s Growth and Future Prospects
With this approval, Aurobindo Pharma now has a total of 599 ANDA approvals from USFDA. The company continues to strengthen its position in the global pharmaceutical market with its robust product portfolio spread over seven major therapeutic areas. Aurobindo Pharma’s commitment to innovation and quality is evident in its extensive list of manufacturing and packaging facilities approved by leading regulatory agencies worldwide.
Aurobindo Pharma Limited remains dedicated to its mission of delivering high-quality, affordable medications to patients globally. With the launch of Perampanel Tablets, the company is poised to further its growth and contribute to improved patient outcomes in the epilepsy treatment landscape.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Aurobindo Pharma Limited
Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Aurobindo posts a 3.5% three-month gain, but softens in the last few weeks. Revenue grows at 10.7% and profits at 22.1% CAGR. The market consistently rewards this kind of compounding. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gives back 0.4% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Both the business and the stock move in the right direction. Revenue grows at 10.7%, profits at 22.1%, and the PEG sits at 1.17 — below its growth rate. That combination is rare. Check Fundamentals of Aurobindo Pharma Limited.
AUROPHARMA
Aurobindo Pharma Limited Receives Final Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
Aurobindo Pharma Limited (NSE: AUROPHARMA) receives final approval from USFDA for Beclomethasone Dipropionate HFA Inhalation Aerosol.
Aurobindo Pharma Limited (NSE: AUROPHARMA) announced today that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg, a generic equivalent of QVAR® Inhalation Aerosol 40 mcg and 80 mcg, marketed by Teva Branded Pharmaceutical Products R&D LLC. This marks Aurobindo’s first metered-dose inhaler (MDI) product, signifying a significant milestone in the company’s expansion into complex respiratory therapies and strengthening its capabilities in the inhalation segment.
Manufacturing and Market Potential
The product will be manufactured at Aurobindo Pharma’s Raleigh facility in North Carolina, owned by its wholly-owned step-down subsidiary Aurolife Pharma LLC. The US market for the approved product and newer versions of the reference product, QVAR® Redi Haler, was estimated at US$301 million for the twelve months ended July 2026, according to IQVIA.
Therapeutic Benefits
Beclomethasone Dipropionate HFA Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Indicated for asthma patients who require systemic corticosteroid administration, where adding Beclomethasone Dipropionate HFA Inhalation Aerosol may reduce or eliminate the need for the systemic corticosteroids.
Building on our leadership in Generics, we are now expanding into complex inhalation therapies to create the next wave of differentiated growth in the US market, stated Aurobindo Pharma Limited.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Aurobindo Pharma Limited
Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Aurobindo rises 14.1% over three months, with buying pressure holding steady. Revenue grows at 10.7% and profits at 22.1% CAGR. The market consistently rewards this kind of compounding. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 94% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 10.7%, profits at 22.1%, and the PEG sits at 1.19 — below its growth rate. That combination is rare. Check Fundamentals of Aurobindo Pharma Limited.
AUROPHARMA
Aurobindo Pharma Limited Launches Generic Advair Diskus® in US Market
Aurobindo Pharma Limited (AUROPHARMA) announces the launch of generic Advair Diskus® in the US market by its subsidiary Lannett Company LLC.
Aurobindo Pharma Limited (NSE: AUROPHARMA) is pleased to announce that Lannett Company LLC, a wholly-owned subsidiary, has launched the generic equivalent of Advair Diskus® (fluticasone propionate and salmeterol inhalation powder), a product of GSK plc, in the US market. This marks the first product from Aurobindo’s inhalation pipeline to be commercialized in the US, reflecting the company’s ongoing focus on expanding its portfolio of complex and differentiated inhalation products.
Advair Diskus® for Asthma and COPD
Advair Diskus® in combination therapy is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). This launch is a significant milestone for Aurobindo Pharma as it continues to build its robust portfolio in the respiratory therapeutic area.
Global Pharmaceutical Leader
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients globally in over 150 countries. With 30+ manufacturing and packaging facilities approved by leading regulatory agencies, Aurobindo Pharma remains committed to delivering high-quality, affordable medications worldwide.
For more information, please visit www.aurobindo.com. For further inquiries, contact Investor Relations | Corporate Communications at Phone: +91 40 667 51211 | 66725000, Email: [email protected].
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Aurobindo Pharma Limited
Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Aurobindo gains 15.3% over three months and trades near its 52-week highs. Revenue grows at 10.7% and profits at 22.1% CAGR. The market consistently rewards this kind of compounding. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 94% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 10.7%, profits at 22.1%, and the PEG sits at 1.15 — below its growth rate. That combination is rare. Check Fundamentals of Aurobindo Pharma Limited.
-
ADFFOODS2 days agoAdf Foods Limited (adffoods) to Install 950 Kwp Rooftop Solar Plant at Surat Facility
-
Apparel Manufacturing3 days agoNandani Creation Limited (jaipurkurt) Outlines Next Growth Phase
-
Basic Materials2 days agoSambahv Steel Tubes Limited (sambhv) Q2 FY27: Highest-ever Sales Volume for Value Added Products
-
Auto Parts1 day agoSedemac Mechatronics Limited Achieves Highest-ever Quarterly and TTM Sales of Control-intensive Ecus
-
AUROPHARMA1 day agoAurobindo Pharma Limited Receives Final Approval for Perampanel Tablets from USFDA
-
Credit Services1 day agoOnemi Technology Solutions Limited (kissht) Q2fy27 Business Update: User Base and AUM Surge
-
AUGMONT1 day agoAugmont Enterprises Limited (augmont) Wins First-ever ‘best Digital and E-commerce Company of the Year’ Award